Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)

January 04, 2015
Lung Cancer
Maria Quejada, MD
Edward Cancer Center - Naperville
Edward Cancer Center - Plainfield
Nancy Knowles Cancer Center - Elmhurst

This randomized phase III trial studies how well erlotinib hydrochloride vs observation in treating patients with stage IB-IIIA non-small cell lung cancer that has been completely removed by surgery. Erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Sponsor: Alliance for Clinical Trials in Oncology

  • Previously registered to ALCHEMSIT A151216, with the result of lung cancer harboring an EGFR exon 19 deletion or L858R mutation
  • Complete recovery from surgery and standard post-operative therapy (if required); the time between date of surgery and randomization must be at least 28 days and no more than 90 days if no adjuvant chemotherapy was administered, 180 days if adjuvant chemotherapy was administered, and 240 days if adjuvant chemotherapy and radiation therapy was administered

10-12 years

Accepting Participants
Kathy Seymour, BSN